Update on the use of pramipexole in the treatment of Parkinson’s disease

Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.

• Publication year

  2008

• Venue

  Neuropsychiatric Disease and Treatment

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/NDT.S2325PMID 18728740PMCID 2518382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valvular heart disease.

  2019cited by this paper
• Pramipexole and levodopa in early parkinson’s disease

  2012cited by this paper
• [Apathy in Parkinson's disease].

  2010cited by this paper
• Long‐term follow‐up of impulse control disorders in Parkinson's disease

  2008cited by this paper
• Single dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsiveness

  2008cited by this paper
• Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.

  2007cited by this paper
• Pramipexole in Levodopa-treated Parkinson Disease Patients of African, Asian, and Hispanic Heritage

  2007cited by this paper
• Drug adverse events and drop-out risk: a clinical case.

  2007cited by this paper
• Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.

  2007cited by this paper
• Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid.

  2007cited by this paper
• Impact of pramipexole on the onset of levodopa‐related dyskinesias

  2007cited by this paper
• Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

  2007influential reference
• DOPAMINE AGONISTS AND CARDIAC VALVULOPATHY IN PARKINSON DISEASE: A CASE-CONTROL STUDY

  2007cited by this paper
• Risk factors for somnolence, edema, and hallucinations in early Parkinson disease

  2007influential reference
• Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.

  2007cited by this paper
• Risk factors for the development of pedal edema in patients using pramipexole.

  2007cited by this paper
• Dopamine agonists and the risk of cardiac-valve regurgitation.

  2007cited by this paper
• Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader‐blinded monocenter echocardiography study

  2007cited by this paper
• Pathological gambling associated with dopamine agonist use in restless legs syndrome.

  2007cited by this paper
• Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole.

  2006cited by this paper
• Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.

  2006cited by this paper
• Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.

  2006cited by this paper
• Avoidance of solid food in weight losing older patients with Parkinson's disease.

  2006cited by this paper
• Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.

  2006cited by this paper
• Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

  2006cited by this paper
• Association of dopamine agonist use with impulse control disorders in Parkinson disease.

  2006cited by this paper
• Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2‐receptor agonist pramipexole

  2006cited by this paper
• Gambling and Parkinson disease.

  2006cited by this paper
• Increase in body weight after pramipexole treatment in Parkinson's disease

  2006cited by this paper
• Use of pramipexole in REM sleep behavior disorder: results from a case series.

  2006cited by this paper
• A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.

  2006cited by this paper
• Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.

  2006influential reference
• Weight loss in Parkinson’s disease

  2006cited by this paper
• Sleep episodes and daytime somnolence as result of individual susceptibility to different dopaminergic drugs in a PD patient: a polysomnographic study.

  2005cited by this paper
• Pathological gambling caused by drugs used to treat Parkinson disease.

  2005cited by this paper
• Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.

  2005influential reference
• The role of radiotracer imaging in Parkinson disease.

  2005cited by this paper
• Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add‐on to l‐dopa therapy

  2005cited by this paper
• Long‐term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial

  2005influential reference
• Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial

  2005cited by this paper
• Sudden uncontrollable somnolence and medication use in Parkinson disease.

  2005influential reference
• Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.

  2005cited by this paper
• Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection.

  2005cited by this paper
• A systematic review of prevalence studies of dementia in Parkinson's disease

  2005cited by this paper
• The role of radiotracer imaging in Parkinson disease.

  2005cited by this paper
• Antidepressant studies in Parkinson's disease: A review and meta‐analysis

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.

  2005cited by this paper
• Pramipexole v. Levodopa as Initial Treatment for Parkinson’s Disease: A Randomized Clinical-Economic Trial

  2004cited by this paper
• Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor

  2004cited by this paper
• Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.

  2004cited by this paper
• Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.

  2004cited by this paper
• Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.

  2004cited by this paper
• Pramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms

  2004cited by this paper
• Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non‐ergot agonists may also not be spared

  2004cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

  2004influential reference
• Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease

  2004cited by this paper
• Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.

  2003cited by this paper
• Pramipexole in comparison to l-dopa: a neuropsychological study

  2003cited by this paper
• Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

  2003cited by this paper
• Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson’s Disease

  2003cited by this paper
• The effects of pramipexole in REM sleep behavior disorder

  2003cited by this paper
• Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study

  2003cited by this paper
• Pramipexole in Routine Clinical Practice

  2003cited by this paper
• Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

  2003cited by this paper
• Epworth sleepiness scale?

  2003cited by this paper
• Randomized, double‐blind, 3‐month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor

  2003influential reference
• Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease

  2003cited by this paper
• Cabergoline, Pramipexole and Ropinirole Used as Monotherapy in Early Parkinson’s Disease

  2003cited by this paper
• Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

  2003influential reference
• Weight loss in Parkinson's disease

  2003cited by this paper
• Apathy in Parkinson’s disease

  2002cited by this paper
• Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.

  2002cited by this paper
• Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study

  2002influential reference
• Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil

  2002cited by this paper
• Sleep attacks in patients taking dopamine agonists: review

  2002cited by this paper
• Pramipexole in treatment-resistant depression: a 16-week naturalistic study.

  2002influential reference
• Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

  2002cited by this paper
• Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics

  2002cited by this paper
• Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease.

  2002cited by this paper
• The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease

  2001cited by this paper
• The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.

  2001cited by this paper
• Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Neuroprotective effects of D3 dopamine receptor agonists.

  2001cited by this paper
• Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD

  2001cited by this paper
• The use of pramipexole in Parkinson's disease: are its actions D(3) mediated?

  2001cited by this paper
• Switching from pergolide to pramipexole in patients with Parkinson's disease

  2001cited by this paper
• Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications

  2000cited by this paper
• An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease

  2000cited by this paper
• Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection

  2000cited by this paper
• Clinical characteristics of pramipexole-induced peripheral edema.

  2000cited by this paper
• What contributes to quality of life in patients with Parkinson's disease?

  2000influential reference
• Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

  2000cited by this paper
• The use of dopamine agonists in very elderly patients with Parkinson's disease

  2000cited by this paper
• Health related quality of life in Parkinson's disease: a prospective longitudinal study

  2000cited by this paper
• Pramipexole‐induced somnolence and episodes of daytime sleep

  2000cited by this paper
• A Comparison of Dopamine Agonists and Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease

  2000cited by this paper
• Apomorphine: An underutilized therapy for Parkinson's disease

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• Range of neuropsychiatric disturbances in patients with Parkinson’s disease

  1999cited by this paper

• Therapeutic Potential and Mechanisms of Puerarin in Liver Disease: A Comprehensive Review of Pharmacological Effects and Drug Delivery Innovations

  2025cites this paper
• A novel nanocomposite Lf-DA-MSN-PF127 aided the delivery of dopamine for the treatment of Parkinson's disease in a rat model

  2025cites this paper
• 2-Heteroarylethylamines in medicinal chemistry: a review of 2-phenethylamine satellite chemical space

  2024cites this paper
• Drug repurposing for neurodegenerative diseases.

  2024cites this paper
• Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson’s Disease

  2024cites this paper
• Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden

  2023cites this paper
• Polyvinylpyrrolidone-Capped Copper Oxide Nanoparticles-Anchored Pramipexole Attenuates the Rotenone-Induced Phenotypes in a Drosophila Parkinson’s Disease Model

  2023cites this paper
• P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease

  2022cites this paper
• Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial

  2022cites this paper
• Thiazoles: A Retrospective Study on Synthesis, Structure-activity Relationship and Therapeutic Significance

  2022cites this paper
• Estimation of Pramipexole Dihydrochloride in Tablet Formulation by the Developed Reverse Phase High Performance Liquid Chromatography Method and its Validation

  2022cites this paper
• Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.

  2021cites this paper
• Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?

  2021cites this paper
• Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update

  2021cites this paper
• The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy.

  2021cites this paper
• Synergy Screening Identifies a Compound That Selectively Enhances the Antibacterial Activity of Nitric Oxide

  2020cites this paper
• ‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine

  2020cites this paper
• Dopamine agonists in treatment of Parkinson's disease: an overview

  2020cites this paper
• Pharmacology of Dopamine and Its Receptors

  2020cites this paper
• Guidelines for the Use of Parkinsonian Drugs (in USA)

  2020cites this paper
• Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review

  2020cites this paper
• The Effect of Physical Exercise on Non-Motor Symptoms of Parkinson’s Disease: An Article Review

  2020cites this paper
• Dissolution-Controlled Salt of Pramipexole for Parenteral Administration: In Vitro Assessment and Mathematical Modeling

  2019cites this paper
• Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and Conundrums.

  2019cites this paper
• Review of preclinical studies on pediatric general anesthesia-induced developmental neurotoxicity.

  2017cites this paper
• Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder

  2017cites this paper
• Successful Treatment of a Child with Difficult-to-Treat Chronic Selective Mutism Using Pramipexole

  2017cites this paper
• Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus

  2017cites this paper
• Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials

  2017cites this paper
• Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives

  2016cites this paper
• Management of Parkinson׳s disease: Current and future pharmacotherapy.

  2015cites this paper
• Parkinson’s disease: a review of non-motor symptoms

  2015cites this paper
• Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

  2014cites this paper
• The benefits of pramipexole selection in the treatment of Parkinson’s disease

  2014influential citation
• Preclinical Modeling of Treatment-induced Impulsivity in Parkinson's Disease

  2013influential citation
• Influence of pramipexole on probability discounting and ventral pallidal function: Assessments in Parkinsonian-like rats

  2013cites this paper
• Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole

  2012cites this paper
• Dyskinesia in Parkinson's Disease Therapy

  2012cites this paper
• Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease

  2012cites this paper
• Validated ultra-performance liquid chromatography tandem mass spectrometry method for the determination of pramipexole in human plasma.

  2010cites this paper
• 13 Drugs that affect autonomic functions or the extrapyramidal system

  2007cites this paper